GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Research & Development

CNTB (Connect Biopharma Holdings) Research & Development : $29.26 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Connect Biopharma Holdings's Research & Development for the six months ended in Dec. 2024 was $15.94 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was $29.26 Mil.

Connect Biopharma Holdings Research & Development Historical Data

The historical data trend for Connect Biopharma Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Research & Development Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 23.10 80.50 96.63 53.00 29.26

Connect Biopharma Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 45.78 26.64 26.36 13.32 15.94

Connect Biopharma Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $29.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings  (NAS:CNTB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Connect Biopharma Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Connect Biopharma Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Connect Biopharma Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Research & Development
Comparable Companies
IPSC XLO ATRA ITRM FBRX RNTX MURA CAMP AKTX VRCA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130
Website
https://www.connectbiopharm.com
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.